

February 25, 2022  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## **Response to marketing approvals of generic products**

TOKYO, Japan, February 25, 2022 -- SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "SymBio") today announced that SymBio, in coordination with Eagle Pharmaceuticals, Inc. (Headquarters: Woodcliff Lake, NJ, "Eagle"), provided a written notice regarding its concerns about the possibility of patent infringement to the makers of four generic bendamustine hydrochloride products which were approved by Japan's Ministry of Health, Labour and Welfare on February 15, 2022. Under the license agreement entered into between SymBio and Eagle in September 2017, SymBio obtained the exclusive rights to develop and commercialize the patent-protected ready-to-dilute ("RTD") liquid formulation and rapid infusion ("RI") administration of bendamustine hydrochloride in Japan. SymBio, in cooperation with Eagle Pharmaceuticals, Inc., will take appropriate legal action against any infringement of applicable patents.

### **[Contact]**

Investor Relations

Tel: +81 (0)3 5472 1125